Cargando…

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease

Gaucher disease (GD) is caused by a deficiency of glucocerebrosidase and the consequent lysosomal accumulation of unmetabolized glycolipid substrates. Enzyme-replacement therapy adequately manages the visceral manifestations of nonneuronopathic type-1 Gaucher patients, but not the brain disease in n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marshall, John, Sun, Ying, Bangari, Dinesh S, Budman, Eva, Park, Hyejung, Nietupski, Jennifer B, Allaire, Amy, Cromwell, Mary A, Wang, Bing, Grabowski, Gregory A, Leonard, John P, Cheng, Seng H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923322/ https://www.ncbi.nlm.nih.gov/pubmed/26948439 http://dx.doi.org/10.1038/mt.2016.53

Ejemplares similares

Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
por: Cabrera-Salazar, Mario A., et al.
Publicado: (2012)

Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease
por: Dai, Mei, et al.
Publicado: (2016)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
por: Ashe, Karen M., et al.
Publicado: (2011)

Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
por: Sun, Ying, et al.
Publicado: (2011)

Neuronopathic Gaucher disease: Beyond lysosomal dysfunction
por: Arévalo, Nohela B., et al.
Publicado: (2022)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy
por: Boddupalli, Chandra Sekhar, et al.
Publicado: (2022)

A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
por: Fujii, Takahiro, et al.
Publicado: (2021)

Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: A survey-based study
por: Koto, Yuta, et al.
Publicado: (2023)

Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014)

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study
por: Narita, Aya, et al.
Publicado: (2016)

Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease
por: Zigdon, Hila, et al.
Publicado: (2015)

Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease
por: Mhanni, A.A., et al.
Publicado: (2015)

Correction: Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan
por: Koto, Yuta, et al.
Publicado: (2023)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
por: Sun, Ying, et al.
Publicado: (2020)

Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report
por: Ceravolo, Ferdinando, et al.
Publicado: (2017)

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative
por: Collin-Histed, Tanya, et al.
Publicado: (2023)

Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
por: Baccam, Gabriel C., et al.
Publicado: (2022)

Drosophila melanogaster Mutated in its GBA1b Ortholog Recapitulates Neuronopathic Gaucher Disease
por: Cabasso, Or, et al.
Publicado: (2019)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease
por: Donald, Aimee, et al.
Publicado: (2022)

Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
por: Messelodi, Daria, et al.
Publicado: (2023)

Glucosylceramide synthase maintains influenza virus entry and infection
por: Drews, Kelly, et al.
Publicado: (2020)

Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021)

Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein
por: Uemura, Norihito, et al.
Publicado: (2015)

Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
por: Degnan, Andrew J., et al.
Publicado: (2019)

Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitis
por: Melamed, Sharon, et al.
Publicado: (2020)

Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses
por: Dubot, Patricia, et al.
Publicado: (2020)

In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020)

A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease
por: Zhang, Zhenting, et al.
Publicado: (2022)

The GBA p.G85E mutation in Korean patients with non-neuronopathic Gaucher disease: founder and neuroprotective effects
por: Kim, Yoo-Mi, et al.
Publicado: (2020)

ARF6 Regulates Neuron Differentiation through Glucosylceramide Synthase
por: Li, Lu, et al.
Publicado: (2013)

New Insights on Glucosylceramide Synthase in Cancer Drug Resistance and Myelosuppression
por: Gupta, Vineet, et al.
Publicado: (2013)

Glucosylceramide Synthase Is Involved in Development of Invariant Natural Killer T Cells
por: Popovic, Zoran V., et al.
Publicado: (2017)

Glucosylceramide Associated with Gaucher Disease Forms Amyloid-like Twisted Ribbon Fibrils That Induce α-Synuclein Aggregation
por: Paul, Ashim, et al.
Publicado: (2021)

Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease
por: Srikanth, Manasa P., et al.
Publicado: (2020)

Increased Hepatic Insulin Action in Diet-Induced Obese Mice Following Inhibition of Glucosylceramide Synthase
por: Yew, Nelson S., et al.
Publicado: (2010)

Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase
por: Nicholson, K M, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_5trg2bfn5md2eoiejukf4n5g1o